These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 4613968

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Comparison between the effects of L-dopa, prodipine and amantadine on the serum and CSF amino acid levels in Parkinson's disease (author's transl)].
    Gründig E, Gerstenbrand F.
    Wien Klin Wochenschr; 1980 Dec 19; 92(24):868-71. PubMed ID: 7222702
    [Abstract] [Full Text] [Related]

  • 3. The treatment with L-dopa and amantadine in Parkinson's disease.
    Pendefunda G, Pollingher B, Stefanache F, Gavril A, Oprisan C, Merling M, Nemteanu E, Ciunru M, Koropitzer I.
    Ther Hung; 1975 Dec 19; 23(1):12-6. PubMed ID: 1105871
    [No Abstract] [Full Text] [Related]

  • 4. [Modification of Parkinson tremor by budipine. A comparative study with amantadine].
    Iizuka J, Fischer R.
    Nervenarzt; 1986 Mar 19; 57(3):184-6. PubMed ID: 3515215
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Drug management of Parkinson's disease.
    Kishore A, Snow BJ.
    Can Fam Physician; 1996 May 19; 42():946-52. PubMed ID: 8688697
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Current therapy of Parkinson's disease.
    Ajax T, Rodnitzky R, Dobson J.
    Iowa Med; 1997 Jan 19; 87(1):27-9. PubMed ID: 9029838
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Therapy of Parkinson's disease. Practical criteria of treatment].
    Casacchia M, Carolei A, Zamponi A, Agnoli A, Fazio C.
    Recenti Prog Med; 1976 May 19; 60(5):567-84. PubMed ID: 14360
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Amantadine in Parkinson's disease: pro and contra.
    Greulich W, Fenger E.
    J Neural Transm Suppl; 1995 May 19; 46():415-21. PubMed ID: 8821077
    [Abstract] [Full Text] [Related]

  • 16. Amantadine and other antiglutamate agents: management of Parkinson's disease.
    Mov Disord; 2002 May 19; 17 Suppl 4():S13-22. PubMed ID: 12211136
    [No Abstract] [Full Text] [Related]

  • 17. Parkinson's disease: drug therapy.
    Oertel WH, Quinn NP.
    Baillieres Clin Neurol; 1997 Apr 19; 6(1):89-108. PubMed ID: 9426870
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H.
    J Pharmacol Exp Ther; 2004 Jul 19; 310(1):386-94. PubMed ID: 15004218
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.